| Oncopeptides, Inc. |
73657002001 |
Pepaxto (melphalan flufenamide) for intravenous use |
2021-03-01 |
9500.0000 |
None |
1 |
500 |
None |
1 |
None |
None |
None |
None |
Estimated number of patients represent number who might potentially receive this drug in the US |
None |
| Organon |
78206017202 |
SINGULAIR 10 mg tablet 90 count |
2021-07-19 |
684.9000 |
Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing for Singulair from Merck, Organon is not adjusting WAC prices at time of launch. |
None |
14288 |
None |
None |
2021-07-19 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, biosimilars, and select legacy products for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
Total 2018 patients for Moktelukast (generic Singulair) was 7,017,347 - assuming an average yearly patient population growth rate of .6% (annual average in US) and a market share rate of 1% and patients receiving one dosage do not also recieve another dosage strength in the same year the total patient volume in 2021 is 14,288. |
None |
| Organon |
78206017402 |
VYTORIN 10; 10 mg/1; mg/1 Tablet 90 count |
2021-07-19 |
1025.1000 |
Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing for Vytorin from Merck, Organon is not adjusting WAC prices at time of launch. |
None |
60937 |
None |
None |
2021-07-19 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, biosimilars, and select legacy products for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
Total 2021 patients for Ezetimibe (generic Vytorin) was 65,000,000 - assuming a market share rate of .75% and patients receiving one dosage do not also recieve another dosage strength in the same year the total patient volume in 2021 is 60,937. |
None |
| Organon |
78206017502 |
VYTORIN 10; 20 mg/1; mg/1 Tablet 90 count |
2021-07-19 |
1025.1000 |
Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing for Vytorin from Merck, Organon is not adjusting WAC prices at time of launch. |
None |
60937 |
None |
None |
2021-07-19 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, biosimilars, and select legacy products for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
Total 2021 patients for Ezetimibe (generic Vytorin) was 65,000,000 - assuming a market share rate of .75% and patients receiving one dosage do not also recieve another dosage strength in the same year the total patient volume in 2021 is 60,937. |
None |
| Organon |
78206017602 |
VYTORIN 10; 40 mg/1; mg/1 Tablet 90 count |
2021-07-19 |
1025.1000 |
Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing for Vytorin from Merck, Organon is not adjusting WAC prices at time of launch. |
None |
60937 |
None |
None |
2021-07-19 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, biosimilars, and select legacy products for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
Total 2021 patients for Ezetimibe (generic Vytorin) was 65,000,000 - assuming a market share rate of .75% and patients receiving one dosage do not also recieve another dosage strength in the same year the total patient volume in 2021 is 60,937. |
None |
| Organon |
78206017702 |
VYTORIN 10; 80 mg/1; mg/1 Tablet 90 count |
2021-07-19 |
1025.1000 |
Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing for Vytorin from Merck, Organon is not adjusting WAC prices at time of launch. |
None |
60937 |
None |
None |
2021-07-19 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, biosimilars, and select legacy products for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
Total 2021 patients for Ezetimibe (generic Vytorin) was 65,000,000 - assuming a market share rate of .75% and patients receiving one dosage do not also recieve another dosage strength in the same year the total patient volume in 2021 is 60,937. |
None |
| Organon |
78206018102 |
ZOCOR 20 mg/1 Tablet 90 count |
2021-07-19 |
725.4000 |
Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing for Zocor from Merck, Organon is not adjusting WAC prices at time of launch. |
None |
17660 |
None |
None |
2021-07-19 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
Total 2018 patients for Simvastatin (generic Zocor) was 10,407,988 - assuming an average yearly patient population growth rate of .6% (annual average in US) and a market share rate of 1% and patients receiving one dosage do not also recieve another dosage strength in the same year the total patient volume in 2021 is 17,660. |
None |
| Organon |
78206018202 |
ZOCOR 40 mg/1 Tablet 90 count |
2021-07-19 |
725.4000 |
Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing for Zocor from Merck, Organon is not adjusting WAC prices at time of launch. |
None |
17660 |
None |
None |
2021-07-19 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
Total 2018 patients for Simvastatin (generic Zocor) was 10,407,988 - assuming an average yearly patient population growth rate of .6% (annual average in US) and a market share rate of 1% and patients receiving one dosage do not also recieve another dosage strength in the same year the total patient volume in 2021 is 17,660. |
None |
| Organon |
78206017902 |
ZOCOR 80 mg/1 Tablet 90 count |
2021-07-19 |
725.4000 |
Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing for Zocor from Merck, Organon is not adjusting WAC prices at time of launch. |
None |
17660 |
None |
None |
2021-07-19 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
Total 2018 patients for Simvastatin (generic Zocor) was 10,407,988 - assuming an average yearly patient population growth rate of .6% (annual average in US) and a market share rate of 1% and patients receiving one dosage do not also recieve another dosage strength in the same year the total patient volume in 2021 is 17,660. |
None |
| Organon |
78206011901 |
Clarinex 5 mg Tablet 100 ct |
2021-08-16 |
730.0000 |
Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing for Clarinex from Merck, Organon is not adjusting WAC prices at time of launch. |
None |
162500 |
None |
None |
2021-08-16 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, biosimilars, and select legacy products for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
Total 2021 patients for Desloratadine (generic Clarinex) was 32,500,000 - assuming a market share rate of 1% and patients receiving one dosage do not also receive another dosage strength in the same year the total patient volume in 2021 is 162,500. |
None |
| Organon |
78206014501 |
Nexplanon 68 mg Implant 1 ct |
2021-08-16 |
1030.6400 |
Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing for Nexplanon from Merck, Organon is not adjusting WAC prices at time of launch. |
None |
904000 |
None |
None |
2021-08-16 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, biosimilars, and select legacy products for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
To account for the impact of COVID the estimated number of patients in 2019 and 2020 have been averaged resulting in an estimated 904,000 patients annually in the US. |
None |
| Organon |
78206014701 |
Ontruzant 150 mg 1 vial injection |
2021-10-01 |
1324.6600 |
"Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing from Merck, Organon is not adjusting WAC prices at time of launch." |
None |
639 |
None |
None |
2021-10-01 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
None |
None |
| Organon |
78206014801 |
Ontruzant 420 mg 1 vial injection |
2021-10-01 |
3709.0400 |
"Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing from Merck, Organon is not adjusting WAC prices at time of launch." |
None |
639 |
None |
None |
2021-10-01 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
None |
None |
| Organon |
78206016201 |
Renflexis 100 mg solution 1 vial |
2021-10-01 |
753.3900 |
"Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product.
Pricing: Organon is inheriting the pricing from Merck, Organon is not adjusting WAC prices at time of launch." |
None |
24299 |
None |
None |
2021-10-01 |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, for clarity these products being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
None |
None |
| Origin Biosciences Inc. |
73129000101 |
Nulibry (fosdenopterin hydrobromide) for injection 9.5mg/vial |
2021-02-26 |
1369.8600 |
Nulibry is the first and only FDA approved treatment for MoCD Type A, a rare and rapidly progressing, fatal, inborn error of metabolism that often presents with intractable seizures shortly after birth. Origin’s approach will focus on educating pediatric neurologists, neonatologists, geneticists, and all NICU/PICU staff on how to diagnose MoCD Type A within the critical time window, and provide information about treatment with Nulibry. Educational materials will be provided across the patient journey, to both HCPs and to families, and highlight access and affordability support for Nulibry to ensure rapid access to life saving therapy |
None |
20 |
1 |
1 |
None |
None |
None |
None |
The product was not acquired and as such no information is to be disclosed |
None |